Isofol Medical AB (publ) (FRA:5IU)
Germany · Delayed Price · Currency is EUR 0.0536
+0.0032 (6.35%)
At close: Nov 28, 2025
Isofol Medical AB Company Description
Isofol Medical AB (publ) operates as a clinical stage biotech company.
The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer.
Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.
Isofol Medical AB (publ)
| Country | Sweden |
| Founded | 2008 |
| Industry | Pharmaceutical Preparations |
| Employees | 5 |
| CEO | Petter Lindqvist |
Contact Details
Address: Biotech Center Gothenburg, 413 46 Sweden | |
| Phone | 46 0 31 13 73 31 |
| Website | isofolmedical.com |
Stock Details
| Ticker Symbol | 5IU |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Petter Lindqvist | Chief Executive Officer |
| Margareta Hagman | Chief Financial Officer |